Kornimate/medical-research-clean huggingface dataset:
aki biomarkers in coronavirus(covid)-19

Conditions: COVID; Acute Respiratory Failure; Acute Kidney Injury

Summary: this research aims to investigate the role of daily measurement of urinary cell cycle arrest markers and other serum and urinary biomarkers to predict the development of acute kidney injury in critically ill patients with covid-19 and acute respiratory disease.

covid-19 is a rapidly evolving pandemic with approximately 5% of all patients requiring admission to an intensive care unit. in critically ill patients with covid-19, acute respiratory disease and acute kidney injury (aki) are very common. patients with aki have an increased risk of mortality, especially renal replacement therapy (rrt) is required. the latest intensive care national audit \& research centre (icnarc) report shows a 77% icu mortality in patients with covid-19 who require mechanical ventilation and rrt. covid-19 associated aki is still poorly understood. the exact underlying pathophysiology remains unknown. furthermore, there are no specific strategies to prevent or treat aki. management is supportive consisting of fluid and haemodynamic optimization, discontinuation of nephrotoxic drugs and prevention of nephrotoxic exposures. ideally, aki needs to be recognized as early as possible for these supportive measures to be effective. early prediction of aki may be valuable to optimize management and improve outcomes. in critically ill patients without covid-19, the two cell-cycle arrest markers, tissue inhibitor of metalloproteinases-2 (timp-2) and insulin-like growth-factor binding protein 7 (igfbp7), have been shown to predict the development of aki. whether these new biomarkers also predict the development of aki in critically ill patients with covid-19 is unknown. the aim of this project is to explore whether urinary cell cycle arrest markers and other renal biomarkers have a role in predicting aki in critically ill patients with covid-19 and acute respiratory disease. the results will advance the understanding of this disease and serve to develop strategies for individualized management of this high-risk group.

Eligibility criteria:
inclusion criteria: 1. moderate or severe respiratory disease as defined by berlin criteria 2. covid-19 positive 3. age ≥ 18 years exclusion criteria: 1. pre-existing aki 2. severe chronic kidney disease (ckd) with estimated glomerular filtration rate (egfr) \<20ml/min 3. end-stage renal failure on regular dialysis 4. kidney transplant within the last 12 months 5. pregnancy 6. breastfeeding
platelets study: influence of the antiretroviral treatment on the platelet physiology during hiv infection

Conditions: Human Immunodeficiency Virus

Summary: hiv infection is associated with an immune activation and an inflammatory response - despite an active antiretroviral therapy - which may lead notably but not exclusively to cardiovascular diseases. it has been shown that the use of protease inhibitors (pi) instead of non nucleosidic inhibitors (nnrti) may increase the risk of myocardial infarction. platelets may play a role in the occurrence of the inflammatory state: they contain big amounts of chemokines, growth factors, and adhesion proteins. today, the contribution of platelets to the inflammatory state associated with hiv infection has been little studied. thus, it has been shown that platelets in hiv patients are able to release interleukin (il)-18. the group has shown with others that the platelet function could be altered during hiv infection. inversely, it doesn't know how antiretroviral therapy interacts with platelets. the aim of the study is to evaluate, according to the antiretroviral therapy, the impact on the platelets activation markers.


Eligibility criteria:
inclusion criteria: * unchanged antiretroviral therapy for at least one year * plasmatic viral load \< 40 copies/ml. * signature of informed consent exclusion criteria: * hepatitis b virus (hbv) and/or hepatitis c virus (hvc) coinfection

Keywords: human immunodeficiency virus hiv antiretroviral therapy platelets immune activation inflammatory state
does medical cannabis reduce opioid use in adults with pain

Conditions: Opioid Use; Marijuana; Chronic Pain

Summary: the study will examine how medical cannabis use affects opioid analgesic use. this landmark study will be among the first to examine the effect of medical cannabis with different thc/cbd (tetrahydrocannibinol/cannabidiol) content on opioid use as well as adverse events.

this study will examine how medical cannabis use affects opioid analgesic use, with particular attention to thc/cbd (tetrahydrocannibinol/cannabidiol) content and adverse events. we will enroll adults with (a) severe or chronic neuropathic or joint pain, (b) prescribed opioid analgesic use, (c) active certification for medical cannabis, and (d) intends to have soft gel capsule products dispensed at vireo (medical cannabis dispensary) (including a high thc:low cbd product, an equal thc:cbd (tetrahydrocannibinol:cannabidiol) product, and a low thc:high cbd product). over the 14 weeks, data sources will include questionnaires; medical, pharmacy, and prescription monitoring program (pmp) records; and urine samples. the primary independent variable will be type of soft gel capsule product, and the primary outcome will be cumulative opioid analgesic dose.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * english or spanish fluency * actively certified for medical cannabis * intends to have a soft-gel capsule product dispensed at vireo * medical cannabis qualifying conditions or complications of "chronic or severe pain" or "pain that degrades health and functional capability as an alternative to opioid use or substance use disorder" * joint or neuropathic pain * current severe pain * dispensed opioid analgesics within the last 60 days to maintain the integrity of the study, we do not disclose all inclusion criteria to potential participants. exclusion criteria: * inability to provide informed consent * inability to complete study visits over 14 weeks * terminal illness * current or prior psychotic disorder * buprenorphine or methadone treatment for opioid use disorder within the past year * allergies to tapioca or coconut * currently pregnant, planning to become pregnant within the next 3 months, or breastfeeding * condition that is considered by a pharmacist or medical provider to be a contraindication to medical cannabis use (e.g. unstable cardiac arrhythmia or specific drug-use interaction)

Keywords: opioid marijuana cannabis pain
stem cell study for subjects with congestive heart failure

Conditions: Myocardial Ischemia; Congestive Heart Failure; Cardiovascular Disease

Summary: the purpose of this study is to determine if cell therapy with your own cells (autologous cells) delivered with a catheter to regions of the heart with poor blood flow will be safe and if it will improve your ejection fraction and heart failure symptoms.


Eligibility criteria:
inclusion criteria: * subjects 21 to 80 years old (inclusive). * subjects with functional class (nyha) ii or iii ischemic heart failure. * subjects who have attempted "best" cardiac medical therapy including long-acting nitrates, maximal use of beta-adrenergic blocking agents, and angiotensin-converting enzyme (ace)inhibitors without control of symptoms. * subjects must be identified as non-candidates for conventional revascularization by their referring cardiologist. * subjects must have left ventricular ejection fraction \<40% by echocardiography. * all subjects must have a recent coronary angiogram (within the last 6 months) to document the coronary anatomy and insure the presence of coronary disease that is not amenable to standard revascularization procedures. * have serum b-type natriuretic peptide (bnp) level \>100 pg/ml. exclusion criteria: * myocardial infarction (q wave or non-q wave defined as ckmb \>3 times normal) within 30 days of treatment. * successful coronary revascularization procedures within 3 months of study enrollment. * documented stroke or transient ischemic attack (tia) within 60 days of study enrollment. * nyha class iv heart failure and patients with idiopathic or non-ischemic heart failure. * history of severe aortic stenosis (aortic valve area \ 2+); severe mitral stenosis (mitral valve area \ 2+). * implantation of biventricular pacemaker within 90 days of study treatment. * severe co-morbidity associated with a reduction in life expectancy of less than 1 year, such as chronic medical illness (i.e. severe chronic obstructive pulmonary disease, renal failure or cancer).

Keywords: heart stem cells low ef heart attack cardiomyopathy congestive heart failure cardiovascular disease heart failure low ejection fraction
fractional microplasma radiofrequency technology for non-hypertrophic post-burn scars in asians: a prospective study of 95 patients

Conditions: Cicatrix

Summary: a prospective study to evaluate the efficacy and safety of fmrt for treating non-hypertrophic post-burn scars in an asian population.

background: laser therapy is an emerging, minimally invasive treatment for scars. among the various techniques, fractional microplasma radiofrequency technology (fmrt) has proved to be effective for various types of scars and skin conditions such as rhytids, striae distensae, and hyperpigmentation. method: a prospective clinical trial was conducted to evaluate the efficacy and safety of fmrt for treating non-hypertrophic post-burn scars in an asian population. all patients underwent three to five treatment sessions at intervals of 8-16 weeks. the patient and observer scar assessment scales (posas) were use to evaluate changes in the burn scars before and after treatment. intermediate and long-term adverse events were recorded for outcome analysis.

Eligibility criteria:
inclusion criteria: * patients with ≥1-year-old non-hypertrophic burn scars exclusion criteria: * pregnancy or breastfeeding * history of hypertrophic scars or keloids * abnormal medical examination including routine blood count, liver and kidney functions and immune function * history of treatment including surgery, dermabrasion, laser treatment within the past 6 months * the presence of a cardiac pacemaker or other metallic implant near the treatment site.

Keywords: burn scar micro-plasma radiofrequency therapy
effect of perioperative sivelstat administration for liver resection

Conditions: Liver Diseases

Summary: it is reported that sivelstat improved and preserved the postoperative renal function in the orthopedic management. moreover because sivelstat reduced the migration of neutrophil, it improved acute lung injury. during liver resection, pringle maneuver, clamping the hepatoduodenal ligament, was performed. pringle maneuver causes reperfusion injury of the liver. we have a hypothesis that sivelstat prevent the warm shock of reperfusion injury of the liver by pringle maneuver.

whether the incidence of postoperative morbidities, such as liver failure, renal failure, or congestive heart failure, was reduced by administration of perioperative sivelstat.

Eligibility criteria:
inclusion criteria: * liver disease which surgical management was indicated exclusion criteria: * weight loss greater than 10 per cent during the previous 6 months, signs of distant metastasis, or of respiratory, renal or heart disease

Keywords: surgery
the effect of patient's position after intra-tympanic injection on the amount of fluid in the middle ear

Conditions: Sudden Hearing Loss

Summary: during the regular protocol of intra-tympanic injections of dexamethasone to the middle ear due to sudden sensorineural hearing loss, the patients will be sitted once after the injection instead of lying down. they will be then asked to rate their taste as a reference to the amount of fluid leaking to the throat through the eustachian tube.


Eligibility criteria:
inclusion criteria: * patients diagnosed with sudden sensorineural hearing loss, treated using intra-tympanic injection of steroids to the middle ear exclusion criteria: * patients with abnormal sense of taste * middle or inner ear anomaly * eustachian tube dysfunction
effects of manual vs instrument-assisted manipulation on electromyographic activity and sympathetic nervous system

Conditions: Healthy

Summary: this study evaluates the effects of manual and instrument-assisted cervical manipulation on electromyographic activity and sympathetic nervous system. subjects were divided in four groups, one group was submitted to a manual cervical manipulation, other group was submitted to an instrument-assisted cervical manipulation, other group was submitted to a sham manipulation and another group served as control.

the manual manipulation was applied over c3/c4, as the participants were positioned in supine with the cervical spine in a neutral position. slight ipsilateral side flexion and contralateral rotation were introduced until tension was perceived in the tissues at the contact point. a high-velocity, low-amplitude thrust manipulation was directed upward and medially in the direction of the subject's contralateral eye. the instrument-assisted manipulation was applied using a handheld activator iv adjusting instrument. contacts were made firm enough to prevent slipping of the rubber tip but not so firm as to load the spring, in consistence with customary clinical use of the instrument. the spring was then loaded by means of the instrument's trigger mechanism, and the impulse was delivered in an anterosuperior direction, over the posterolateral aspect of the vertebra on the right lamina-pedicle junction of c3. the sham manipulation to the right c3/c4 segment was administered using the same 'set-up' as for the manual manipulation; however, once the barrier was engaged, the head was re-positioned to neutral with no thrust applied. the control group individuals were positioned supine for the same twenty minutes as the other groups and they received no manual contact.

Eligibility criteria:
inclusion criteria: * asymptomatic individuals * age above 18 years. exclusion criteria: * presence of cervical pain * history of surgery and/neck trauma * osteoporosis * current use of anticoagulant therapy * presence of dizziness and/or vertigo * pregnancy * cancer * any other contra-indication to spinal manipulation.

Keywords: manipulation electromyography sympathetic nervous system
consequences of eccentric cycling on exercise-related neuromuscular responses and biomarkers in breast cancer patients

Conditions: Breast Cancer

Summary: this is a monocentric, prospective and interventional study aimed to investigating the physiological responses of eccentric compared to concentric cycling realized 1) at the same metabolic demand and 2) at the same mechanical power output. in order to compare the physiological responses between these two cycling modalities, 3 cycling sessions should be performed for each patient where concentric one will serve as reference / comparison to the eccentric one: * session (a): eccentric cycling * session (b): high intensity concentric cycling realized at the same mechanical power output than eccentric cycling * session (c): low intensity concentric cycling realized at the same metabolic demand than eccentric cycling the 3 sessions will be performed for each patient and order will be randomized.

for each participant, 10 visits will be realized as followed: visit 1: determination of maximal o2 consumption (vo2max) and first familiarization session to eccentric cycling visits 2, 3 and 4: second, third and fourth eccentric cycling familiarization sessions visits 5, 7 and 9: cycling sessions (a), (b) and (c) attributed in a random order visits 6, 8 and 10: post-24h measurements after cycling sessions

Eligibility criteria:
inclusion criteria: * woman who completed (neo)adjuvant chemotherapy since less than 1 year for a breast cancer * woman under hormonotherapy, or menopausal woman, or woman in amenorrhea exclusion criteria: * pregnant and nursing woman * psychiatric, musculoskeletal or neurological disorders * presenting at least one contraindication to the use of the transcranial magnetic stimulation * presenting at least one contraindication to the realisation of the maximum effort test

Keywords: breast cancer eccentric cycling physiological responses
the value of three dimensional echocardiography in congenital cardiac surgery

Conditions: Congenital Heart Disease

Summary: there are few studies evaluating the value of 3d echocardiography in children undergoing congenital cardiac surgery. the aim of this observational study is to describe common and uncommon congenital malformations with the help of 3d echo and compare the findings and the measurements with those obtained with conventional 2d echo.


Eligibility criteria:
inclusion criteria: * all children requiring general anesthesia for congenital heart surgery and in whom informed parental consent has been obtained exclusion criteria: * children with congenital heart disease who do not require heart surgery
free mucogingival graft for isolated root coverage

Conditions: Free Mucogingival Grafts; Gingival Recession; Root Coverage; Periodontal Plastic Surgery

Summary: the goal of this clinical trial is to to describe and evaluate an approach, free mucogingival graft (fmg), in periodontal plastic surgery for root coverage (rc) in lower incisor gingival recessions (gr) with mucogingival conditions and deformities (mcd) that might negatively influence the outcomes of conventional rc procedures.


Eligibility criteria:
inclusion criteria: * healthy patients with deep gr associated with lower incisor mcd. * full mouth plaque and bleeding scores were \<20%. exclusion criteria: patient characteristics: * smoking ≥10 cigarettes a day. * medications or systemic contraindications for oral surgery. * pregnancy. defects: * thin scalloped biotype (and/or) * underlying bone dehiscence (and /or) * generalized gr affecting most sextants.
evaluation of hyperemia with the use of ocular prostaglandin analogues

Conditions: Open Angle Glaucoma; Ocular Hypertension

Summary: this study will evaluate hyperemia and ocular surface tolerability in patients on prostaglandin analogues


Eligibility criteria:
inclusion criteria: * diagnosis of open-angle glaucoma (pseudoexfoliative or pigmentary glaucomas are allowed) or ocular hypertension exclusion criteria: * known contraindication to latanoprost, bimatoprost or travoprost * uncontrolled systemic disease * active ocular disease other than glaucoma or ocular hypertension * pregnant or lactating women or women of childbearing potential not utilizing a medically acceptable form of birth control
dose-response curves between propofol and intraoperative electroencephalographic patterns

Conditions: Propofol Overdose; EEG

Summary: in the world, 230 million surgeries are performed per year and a significant part is performed in patients over 65 years of age. these patients are more labile, especially from the neurocognitive point of view with a high risk to develop neurocognitive complications, such as postoperative delirium. recent studies have linked this type of complication with an overdose of general anesthetics during surgery. for this reason, in recent years, the use of brain function monitors during the intraoperative period has been recommended to adapt the dosage of the drugs to each patient and thus to avoid overdosing of general anesthetics. however, to date, the available monitors that process the electroencephalographic signal are not able to adequately discriminate gradual changes in anesthetic depth. also, no systematic studies have been performed that analyze changes that occur in the electroencephalogram (eeg) signal secondary to increases in complications from general anesthetics. thus, the investigators design this study with the main aim to determine the changes in electroencephalographic patterns induced by a stepped increase of propofol until the burst suppression is reached.

the investigators will carry out a prospective analytical observational clinical study at the clinical hospital of the university of chile. in total 15 patients will be recruited, in who a frontal electroencephalographic signal will be recorded using a sedline® monitor, and propofol concentration will be estimated using the marsh model. first, the concentration of propofol at the loss of consciousness (los) will be recorded in the presence of remifentanil (7.5 ng/ml). then, patients will be intubated and remifentanil will be decreased to 4 ng/ml. after that, the concentration of propofol that caused the los will be maintained for 20 minutes. finally, propofol will be increased in steps of 0.3 mcg/ml for 7 min, until an episode of burst suppression will be observed. in the complete protocol, eeg activity will be acquired using a sedline® monitor.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) physical status 1 or 2 * low-risk surgery exclusion criteria: * bmi \> 35 kg/m2 * benzodiazepines use * epilepsy * psychiatric disorder * kidney disease * liver disease * brain damage

Keywords: propofol general anesthesia eeg burst suppression
early feasibility of the velocity™ percutaneous pavf system

Conditions: Arteriovenous Fistula

Summary: an early feasibility study of the the initial safety and efficacy of the velocity percutaneous arterio-venous fistula (pavf) system when used to percutaneously create an arteriovenous fistula in patients with esrd requiring hemodialysis vascular access.


Eligibility criteria:
inclusion criteria: * age 18 years or older * diagnosed with esrd and currently on hemodialysis for less than 12 months using a central venous catheter for access * eligible for a native surgical brachiocephalic arteriovenous fistula following assessment by the principal investigator and study sponsor * cubital perforating vein diameter of \> 2.5 mm and length \> 10.0 mm * proximal radial artery diameter ≥ 2.0 mm * patient is free of clinically significant conditions or illness within 30 days prior to the av fistula that may compromise the procedure * willing and competent to give written informed consent exclusion criteria: * distance between proximal radial artery and cubital perforating vein \> 3mm * ipsilateral arm systolic blood pressure \< 110 mmhg * known central venous stenosis or central vein narrowing \> 50% ipsilateral to the study extremity * any obstruction of venous outflow from device implant site to the axillary vein * patients with occlusion of the ulnar or radial artery at any level or an abnormal allen's test * any previous dialysis vascular access procedures in the study extremity * history of steal syndrome (hand ischemia) from a previous hemodialysis vascular access of the non-study extremity which required intervention or access abandonment * upper extremity venous occlusion(s) and/or vessel abnormality(ies) of the study extremity that precludes endovascular avf creation as determined by principal investigator or study sponsor * evidence of active systemic infections on day of the procedure or infection at the access site within the past 7 days * history or evidence of severe cardiac disease (nyha functional class iii or iv), myocardial infarction within six months prior to study entry, ventricular tachyarrhythmias requiring continuing treatment, or unstable angina * currently being treated with another investigational device or drug * known adverse effects to sedation and/or anesthesia which cannot be adequately pre-medicated * uncontrolled or poorly controlled diabetes defined as a hba1c \> 10% * hypercoagulable condition, bleeding diathesis or coagulation disorder * receiving anti-coagulant therapy that cannot be safely held in the peri-procedural period * edema of the upper arm of the study extremity * scheduled kidney transplant within 6 months of enrollment * peripheral white blood cell count \< 1.5 k/mm3 or platelet count \< 75,000 cells/mm3 * current diagnosis of carcinoma (defined as in remission \< 1 year) * pregnant or currently breast feeding * history of substance abuse or anticipated to be non- compliant with medical care or study requirements based on investigator judgment * allergies to niti alloy or any of the components of the velocity implant or delivery system * written informed consent not obtainable